INVESTORS & MEDIA

Press Releases

Date Title and Summary View
Toggle Summary Atara Biotherapeutics to Present 2020 Key Milestones and Progress in Bringing Off-The-Shelf, Allogeneic T-Cell Immunotherapies to Patients in Need at the 38th Annual J.P. Morgan Healthcare Conference
Key milestones anticipated across Atara’s four strategic priorities in 2020 Continued investment in EBV T-cell platform to develop off-the-shelf, allogeneic CAR T immunotherapies leveraging favorable EBV T-cell safety, expansion, trafficking and persistence characteristics SOUTH SAN FRANCISCO,
View HTML
Toggle Summary Atara Biotherapeutics Reports Updated Long-Term Clinical Results from a Tab-cel® Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society Of Hematology (ASH) Annual Meeting
61 patients with diverse EBV-associated diseases, including 26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel ® (tabelecleucel) EAP study Tab-cel ® was generally well-tolerated in all patients with EBV+ PTLD and other EBV-associated diseases Estimated two-year overall
View HTML
Toggle Summary Atara Biotherapeutics to Participate at Evercore ISI Second Annual HealthCONx Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Pascal Touchon , the
View HTML
Toggle Summary Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress
SOUTH SAN FRANCISCO, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today reported financial results for the
View HTML
Toggle Summary Atara Biotherapeutics to Present Tab-cel® Long-Term Clinical Outcomes from a Multicenter Expanded Access Protocol (EAP) Study for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) at the 61st American Society of Hematology (ASH) Annual Meeting
26 relapsed/refractory EBV+ PTLD patients were treated in a multicenter tab-cel ® EAP study including a subgroup of 22 patients who would have likely met eligibility criteria for Atara’s ongoing tab‑cel ® Phase 3 studies An overall response rate (ORR) of 55 and 82 percent was observed in this
View HTML
Toggle Summary Atara Biotherapeutics to Announce Third Quarter 2019 Operational Progress and Financial Results on Thursday, November 7, 2019
Live Conference Call and Webcast at 8:00 a.m. EST SOUTH SAN FRANCISCO, Calif. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral
View HTML
Toggle Summary Atara Biotherapeutics Announces Executive Departures
SOUTH SAN FRANCISCO, Calif. , Oct. 25, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced the departures of Dr.
View HTML
Toggle Summary Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
Enrollment in the fourth and final planned Phase 1 dose escalation cohort completed ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, believed to play a role in the pathogenesis of multiple sclerosis Conference call and webcast today at 3:30 p.m. CEST / 9:30 a.m.
View HTML
Toggle Summary Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
ATA188 targets Epstein-Barr Virus (EBV)-infected B cells, which we believe play a fundamental role in the pathogenesis of multiple sclerosis Conference call and webcast to discuss results Friday, September 13, 2019 , at 3:30 p.m. CEST / 9:30 a.m. EDT SOUTH SAN FRANCISCO, Calif. , Sept.
View HTML
Toggle Summary Atara Biotherapeutics to Participate in Citi 14th Annual Biotech Conference
SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today announced that Pascal Touchon , the
View HTML